Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT061 multiple-dose study in moderate to severe chronic plaque psoriasis
2008-007458-37Phase 2Completed
- Sponsor
- Biotest AG
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tregalizumab in psoriasis (7 arms), sponsored by Biotest AG. Primary endpoint: PASI 75 response rate at end of treatment. Started Sep 2009; status: completed.
02
Drugs
tregalizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2008-007458-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007458-37.